

## REMARKS

The English language application filed herewith is a translation into English of the parent application (International Application No. PCT/EP2004/014143 filed on December 13, 2004). References herein to paragraph numbers of the parent application relate to the English language version.

### A. Amendments in the specification

Amendment of the specification by insertion of new paragraph [0000] is requested to provide cross-reference to, claim benefit of, and incorporate by reference prior applications in accordance with 37 C.F.R. §§ 1.55, 1.57(a) and 1.78(a).

### B. Amendments in the claims

The following claims are now pending in the present application: Claims 10–21, all new according to this amendment.

Claims 1–9 of the application as originally filed in the international application are cancelled without prejudice. As will be evident from remarks below, the subject matter of certain of these claims is presented in amended form in some of the new claims.

Each of Claims 10–20 finds support in the parent application as filed.

Claim 10 will be seen to correspond substantively to Claim 2 as originally filed, except for the following changes:

- “pharmaceutically acceptable” as a descriptor of a salt, which finds support in the specification as filed at least at paragraph [0024]; the term “pharmaceutically acceptable salt” is defined at paragraph [0026];
- “at least one pharmaceutically acceptable carrier or adjuvant” as a component of the claimed pharmaceutical composition, which finds support in the specification as filed at least at paragraph [0058];
- in the recitation of the prodrug, a Markush group of R<sup>1</sup> substituents that is a subset of those recited in original Claim 2;
- in the recitation of the prodrug, “a salt thereof”, to clarify that salts of prodrugs of the formula shown, as well as salts of (S)-2-N-propylamino-5-hydroxytetralin itself, are embraced; in this regard, reference is made to the specification as filed at paragraph [0068], which states that salts or prodrugs can be suspended and injected, for example as salt crystals.

Claim 11, reciting a composition comprising (S)-2-N-propylamino-5-hydroxytetralin or a salt thereof, finds support throughout the specification as originally filed.

Claim 12 will be seen to correspond substantively to Claim 3 as originally filed, except that the composition of Claim 11 is refocused on a composition that comprises a prodrug of (S)-2-N-propylamino-5-hydroxytetralin having R<sup>1</sup> as defined therein, or a salt thereof. Previously, Claim 3 also embraced compositions comprising (S)-2-N-propylamino-5-hydroxytetralin itself or a salt thereof. Such compositions are now the subject of Claim 11.

Claim 13 will be seen to correspond substantively to Claim 4 as originally filed.

Claim 14, reciting that the (S)-2-N-propylamino-5-hydroxytetralin or salt or prodrug thereof is present as a pure (S)-enantiomer, finds support in the specification as originally filed at least at paragraph [0024]; the term "pure (S)-enantiomer" is defined at paragraph [0025].

Claims 15–17, drawn to a method for treatment or prophylaxis of a disease or for ablation, replace "Swiss form" claims previously presented as Claims 5–8. The compounds used according to the method of Claim 15 conform to those recited in Claim 10. The list of diseases recited in Claim 15 is drawn from original Claim 5. Claims 16 and 17 will be seen to correspond substantively to Claims 6 and 7 respectively, as originally filed.


Claim 18, which relates to a method for treating a disease that responds to therapy by dopamine or dopamine agonists, finds support in the specification as filed at least at paragraphs [0023]–[0024].

Claims 19–21 relate to a compound *per se* and find support throughout the specification as filed. It will be noted that Claims 19 and 20 correspond in scope to the prodrugs defined in Claims 10 and 12 respectively. Claim 21 finds specific support in the specification as filed at least at paragraph [0027].

No new matter is added, and no changes in inventorship are believed to result, by the present amendment. Examination of the present application is requested following entry of this amendment.

6102-000034/US/NP  
Serial No. to be assigned  
Preliminary amendment (Amendment A)  
July 28, 2006

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'B. Schmidt', with a long horizontal flourish extending to the right.

Bradford P. Schmidt  
Attorney for Applicant  
Reg. No. 42,128  
Tel. 262-238-5141